Loading clinical trials...
Loading clinical trials...
An Extension to a Phase II Study to Determine the Safety and Anti-Leukemic Effects of STI571 in Adult Patients With Philadelphia Chromosome Positive Leukemia Including Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Accelerated Phase Chronic Myeloid Leukemia
Conditions
Interventions
STI571 400 mg
STI571 600 mg
Locations
12
United States
Dana Faber Cancer Institute
Boston, Massachusetts, United States
New York Presbyterian Hospital
New York, New York, United States
Oregon Health & Sciences University
Portland, Oregon, United States
MD Anderson Cancer Center, University of Texas
Houston, Texas, United States
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Poitiers, France
Start Date
August 9, 1999
Primary Completion Date
September 23, 2013
Completion Date
September 23, 2013
Last Updated
July 22, 2021
NCT05564390
NCT07320235
NCT06782542
NCT06284486
NCT07295951
NCT07523555
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions